Esperion Therapeutics Inc.

201 articles about Esperion Therapeutics Inc.

• Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List

  10/25/2019

  Esperion announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd.

• 

  Clinical Catch-Up: September 2-8

  9/9/2019

  Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.

• Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid

  9/5/2019

  Esperion announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial.

• 

  Clinical Catch-Up: August 25-30

  9/3/2019

  Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.

• Esperion Announced on August 27, 2019 Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  8/30/2019

  Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.

• Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes

  8/29/2019

  Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.

• Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results

  8/8/2019

  Esperion provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.

• Esperion to Present at the BTIG Biotechnology Conference

  8/6/2019

  Esperion announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time.

• Esperion to Report Second Quarter 2019 Financial Results August 8, 2019

  7/30/2019

  Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.

• Esperion and Oberland Capital Announce $200 Million Funding Agreement

  6/26/2019

  Esperion and an investor group led by Oberland Capital Management LLC announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.

• Esperion Announces the Appointment of Tracy M. Woody to Board of Directors

  5/30/2019

  Esperion announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders.

• Esperion to Participate in Upcoming June 2019 Investor Conferences

  5/28/2019

  Esperion announced that the company will participate in analyst-led fireside chats with investors at the following conferences

• Esperion to Participate in Upcoming May 2019 Investor Conferences

  5/10/2019

  Esperion today announced that the company will participate in analyst-led fireside chats with investors at the following conferences

• Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results

  5/8/2019

  Esperion provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019.

• Esperion to Host Analyst and Investor Day Event on May 30

  5/7/2019

  Esperion announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time.

• Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review

  5/5/2019

  Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver

• Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors

  4/24/2019

   Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached their fiduciary duties to shareholders. 

• Esperion to Present at the Needham & Company 18th Annual Healthcare Conference

  4/2/2019

  Esperion, the Lipid Management Company announced that the company will participate in an analyst-led fireside chat with investors at the Needham & Company 18th Annual Healthcare Conference in New York, NY on Tuesday, April 9, 2019, at 11:20 a.m. Eastern Time.

• Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results

  4/1/2019

  Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant

• 

  Esperion’s Cholesterol Drug Looks Great in Phase III, but Faces Tough Market

  3/19/2019

  Esperion, based in Ann Arbor, Mich., announced results from its Phase III Study 2 of bempedoic acid at the American College of Cardiology (ACC) annual meeting.